<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) in children is often considered as a variant of <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and frequently treated as such </plain></SENT>
<SENT sid="1" pm="."><plain>However, there are very few reported data on the outcome following <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> treatment </plain></SENT>
<SENT sid="2" pm="."><plain>We analyzed 20 consecutive cases of de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> treated in Denmark according to the NOPHO <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> protocols </plain></SENT>
<SENT sid="3" pm="."><plain>The results were compared with those obtained in 31 children with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> treated with the same protocols, and with the outcome in 10 children with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> who received allogeneic bone marrow transplantation (BMT) without prior <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> therapy </plain></SENT>
<SENT sid="4" pm="."><plain>Distinction between <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> was made morphologically according to the FAB criteria </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> children were followed for at least 37 months </plain></SENT>
<SENT sid="6" pm="."><plain>The proportion of complete remission in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> was 35 percent vs 74 percent </plain></SENT>
<SENT sid="7" pm="."><plain>(P = 0.005), resistant disease 25 percent vs 10 percent (P = 0.14), <z:hpo ids='HP_0011420'>death</z:hpo> in cytopenia 40 percent vs 16 percent (P= 0.06), and 3-year survival 15 percent vs 35 percent </plain></SENT>
<SENT sid="8" pm="."><plain>(P = 0.11), respectively </plain></SENT>
<SENT sid="9" pm="."><plain>Duration of treatment-related cytopenia was similar in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, except for a longer period of <z:hpo ids='HP_0001882'>leukopenia</z:hpo> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> following the second course of induction </plain></SENT>
<SENT sid="10" pm="."><plain>Seven of 10 MDS children receiving BMT without prior chemotherapy are long-term survivors </plain></SENT>
<SENT sid="11" pm="."><plain>Our data suggest that conventional <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> regimens are associated with a low rate of complete remission, a high risk of <z:hpo ids='HP_0011420'>death</z:hpo> in cytopenia, and a limited curative potential in childhood <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Allogeneic BMT was in contrast associated with a high survival rate </plain></SENT>
<SENT sid="13" pm="."><plain>BMT may, at least in some patients, be performed successfully without prior induction chemotherapy </plain></SENT>
<SENT sid="14" pm="."><plain>The different response to therapy in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> may reflect fundamental biological differences between the two conditions </plain></SENT>
</text></document>